The History, Mechanism, and Perspectives of Nirmatrelvir (PF-07321332): an Orally Bioavailable Main Protease Inhibitor Used in Combination with Ritonavir to Reduce COVID-19-related Hospitalizations

Overview

Journal Med Chem Res

Publisher Springer

Specialty Chemistry

Date 2022 Sep 5

PMID 36060104

Authors

Ryan P Joyce

Vivian W Hu

Jun Wang

Affiliations

Soon will be listed here.

Abstract

The rapid development of effective vaccines to combat the SARS-CoV-2 virus has been an effective counter measure to decrease hospitalization and the mortality rate in many countries. However, with the risk of mutated strains decreasing the efficacy of the vaccine, there has been an increasing demand for antivirals to treat COVID-19. While antivirals, such as remdesivir, have had some success treating COVID-19 patients in hospital settings, there is a need for orally bioavailable, cost-effective antivirals that can be administered in outpatient settings to minimize COVID-19-related hospitalizations and death. Nirmatrelvir (PF-07321332) is an orally bioavailable M (also called 3CL) inhibitor developed by Pfizer. It is administered in combination with ritonavir, a potent CYP3A4 inhibitor that decreases the metabolism of nirmatrelvir. This review seeks to outline the history of the rational design, the target selectivity, synthesis, drug resistance, and future perspectives of nirmatrelvir. Graphical abstract.

Citing Articles

Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates.

Jadhav P, Liang X, Ansari A, Tan B, Tan H, Li K Nat Commun. 2025; 16(1):1604.

PMID: 39948104 PMC: 11825904. DOI: 10.1038/s41467-025-56902-x.

Distal protein-protein interactions contribute to nirmatrelvir resistance.

Lewandowski E, Zhang X, Tan H, Jaskolka-Brown A, Kohaal N, Frazier A Nat Commun. 2025; 16(1):1266.

PMID: 39893201 PMC: 11787374. DOI: 10.1038/s41467-025-56651-x.

Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 M.

Ren J, Zhang Z, Xia Y, Zhao D, Li D, Zhang S Molecules. 2025; 30(2).

PMID: 39860219 PMC: 11767629. DOI: 10.3390/molecules30020351.

Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents.

Kumar V, Zhu J, Chenna B, Hoffpauir Z, Rademacher A, Rogers A J Am Chem Soc. 2025; 147(2):1631-1648.

PMID: 39746101 PMC: 11744766. DOI: 10.1021/jacs.4c11620.

A cell-based Papain-like Protease (PLpro) activity assay for rapid detection of active SARS-CoV-2 infections and antivirals.

Jimenez-Campos A, Maestas L, Velappan N, Beck B, Ye C, Wernsing K PLoS One. 2024; 19(12):e0309305.

PMID: 39724215 PMC: 11670956. DOI: 10.1371/journal.pone.0309305.

References

Heskin J, Pallett S, Mughal N, Davies G, Moore L, Rayment M . Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management. Lancet. 2022; 399(10319):21-22. PMC: 8718360. DOI: 10.1016/S0140-6736(21)02657-X. View

Schooley R, Carlin A, Beadle J, Valiaeva N, Zhang X, Clark A . Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs. Antimicrob Agents Chemother. 2021; 65(10):e0115521. PMC: 8448143. DOI: 10.1128/AAC.01155-21. View

Tan J, George S, Kusov Y, Perbandt M, Anemuller S, Mesters J . 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol. 2013; 87(8):4339-51. PMC: 3624371. DOI: 10.1128/JVI.01123-12. View

Martin J, Mackenzie C, Fletcher D, Gilbert I . Characterising covalent warhead reactivity. Bioorg Med Chem. 2019; 27(10):2066-2074. PMC: 6538824. DOI: 10.1016/j.bmc.2019.04.002. View

Korkmaz B, Lesner A, Wysocka M, Gieldon A, Hakansson M, Gauthier F . Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C. Biochem Pharmacol. 2019; 164:349-367. DOI: 10.1016/j.bcp.2019.04.006. View

Eng H, Dantonio A, Kadar E, Obach R, Di L, Lin J . Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans. Drug Metab Dispos. 2022; 50(5):576-590. DOI: 10.1124/dmd.121.000801. View

Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N . The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet. 2004; 18(6):365-72. DOI: 10.2133/dmpk.18.365. View

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W . Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022; 386(15):1397-1408. PMC: 8908851. DOI: 10.1056/NEJMoa2118542. View

Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y . Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun. 2020; 11(1):4417. PMC: 7474075. DOI: 10.1038/s41467-020-18233-x. View

10.

Callaway E . Heavily mutated Omicron variant puts scientists on alert. Nature. 2021; 600(7887):21. DOI: 10.1038/d41586-021-03552-w. View

11.

Zhao Y, Fang C, Zhang Q, Zhang R, Zhao X, Duan Y . Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell. 2021; 13(9):689-693. PMC: 8533666. DOI: 10.1007/s13238-021-00883-2. View

12.

Silva D, Ribeiro J, De Vita D, Cianni L, Franco C, Freitas-Junior L . A comparative study of warheads for design of cysteine protease inhibitors. Bioorg Med Chem Lett. 2017; 27(22):5031-5035. DOI: 10.1016/j.bmcl.2017.10.002. View

13.

Hung Y, Lee J, Chiu C, Lee C, Tsai P, Hsu I . Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?. Antibiotics (Basel). 2022; 11(2). PMC: 8868411. DOI: 10.3390/antibiotics11020220. View

14.

Zhai Y, Zhao X, Cui Z, Wang M, Wang Y, Li L . Cyanohydrin as an Anchoring Group for Potent and Selective Inhibitors of Enterovirus 71 3C Protease. J Med Chem. 2015; 58(23):9414-20. DOI: 10.1021/acs.jmedchem.5b01013. View

15.

Ma C, Sacco M, Hurst B, Townsend J, Hu Y, Szeto T . Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020; 30(8):678-692. PMC: 7294525. DOI: 10.1038/s41422-020-0356-z. View

16.

Grubaugh N, Hodcroft E, Fauver J, Phelan A, Cevik M . Public health actions to control new SARS-CoV-2 variants. Cell. 2021; 184(5):1127-1132. PMC: 7846239. DOI: 10.1016/j.cell.2021.01.044. View

17.

Li P, Wang Y, Lavrijsen M, Lamers M, de Vries A, Rottier R . SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022; 32(3):322-324. PMC: 8771185. DOI: 10.1038/s41422-022-00618-w. View

18.

Ullrich S, Ekanayake K, Otting G, Nitsche C . Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett. 2022; 62:128629. PMC: 8856729. DOI: 10.1016/j.bmcl.2022.128629. View

19.

Ndao M, Beaulieu C, Black W, Isabel E, Vasquez-Camargo F, Nath-Chowdhury M . Reversible cysteine protease inhibitors show promise for a Chagas disease cure. Antimicrob Agents Chemother. 2013; 58(2):1167-78. PMC: 3910870. DOI: 10.1128/AAC.01855-13. View

20.

Fan K, Ma L, Han X, Liang H, Wei P, Liu Y . The substrate specificity of SARS coronavirus 3C-like proteinase. Biochem Biophys Res Commun. 2005; 329(3):934-40. PMC: 7092912. DOI: 10.1016/j.bbrc.2005.02.061. View